Inovio Pharmaceuticals (INO) 9.75 $INO
Inovio Pharmaceuticals to Host Second Quarter 2014 Financial Results Call on August 11, 2014
PR Newswire - Fri Aug 01, 7:00AM CDT
Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that it will host a conference call to report its second quarter 2014 financial results on Monday, August 11, 2014 at 9:00 AM ET. CEO Dr. J. Joseph Kim and CFO Peter Kies will discuss second quarter earnings, provide a corporate update, and participate in a live Q&A with analysts. The update will include clinical development plans for VGX-3100, Inovio's immune therapy targeting pre-cancers and cancers associated with HPV.
23.2% Return Seen to Date on SmarTrend Inovio Biomedical Call (INO)
Comtex SmarTrend(R) - Tue Jul 29, 9:46AM CDT
SmarTrend identified an Uptrend for Inovio Biomedical (AMEX:INO) on June 6th, 2014 at $9.41. In approximately 2 months, Inovio Biomedical has returned 23.16% as of today's recent price of $11.59.
What Do Short-Sellers Have Against These 3 Companies?
Sean Williams, The Motley Fool - Motley Fool - Mon Jul 28, 10:25AM CDT
The best thing about the stock market is that you can make money in either direction . Historically, stock indexes tend to trend upward over the long term. But when you look at individual stocks, you'll find plenty that lose money over the long...
This Week in Biotech: Puma Sprints, Gilead Sweeps, and Inovio Hits the Mark
Sean Williams, The Motley Fool - Motley Fool - Sat Jul 26, 12:32PM CDT
With the SPDR S&P Biotech Index up 22% over the trailing 12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and...
Upgrade Alert for Inovio Biomedical (INO)
Comtex SmarTrend(R) - Fri Jul 25, 6:55AM CDT
Inovio Biomedical (AMEX:INO) was upgraded from Hold to Buy at Aegis today. The stock closed yesterday at $12.94 on volume of 3.6 million shares, above average daily volume of 1.7 million. Over the past year, Inovio Biomedical has traded in a range of $1.22 to $14.20 and closed yesterday at $12.98, 964% above that low. The 200-day and 50-day moving averages have moved 3.99% higher and 8.45% higher over the past week, respectively.
3 Game-Changing Stories That Shook Investors: Inovio Pharmaceuticals, Gilead Sciences, and GlaxoSmit
George Budwell, The Motley Fool - Motley Fool - Thu Jul 24, 1:05PM CDT
The health care sector exploded with major news events yesterday, fueled by second-quarter earnings, clinical trial updates, and even unexpected regulatory events. Given that the day's headlines seemed to be dominated by Puma Biotechnology 's...
The S&P 500 Closes at Yet Another All-Time Closing High on No Volume
at The Street - Wed Jul 23, 4:34PM CDT
The stock indexes closed mixed on Wednesday with the S&P 500 setting a new all-time closing high.
After Yesterday's Rally of 17.59% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Wed Jul 23, 4:25PM CDT
Inovio Biomedical (AMEX:INO) traded in a range yesterday that spanned from a low of $12.00 to a high of $14.20. Yesterday, the shares gained 17.6%, which took the trading range above the 3-day high of $11.60 on volume of 12.9 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Why Inovio Pharmaceuticals Inc Stock Livened Up Today
Dan Carroll, The Motley Fool - Motley Fool - Wed Jul 23, 1:21PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Inovio Pharmaceuticals , a clinical-stage...
Inovio Declares Spin-Laden Victory With DNA Vaccine
at The Street - Wed Jul 23, 9:17AM CDT
Inovio's analysis of the VGX-3100 study omits an unknown number of patients, calling the results into question.
Inovio Pharmaceuticals HPV Immunotherapy Achieves Primary Efficacy Endpoint in Randomized Phase II Cervical Dysplasia Trial
PR Newswire - Wed Jul 23, 8:15AM CDT
Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) today announced successful results from its randomized, double-blind, placebo-controlled phase II trial of VGX-3100 in women with biopsy-proven cervical intraepithelial neoplasia 2/3 (CIN2/3) associated with human papillomavirus (HPV) types 16 or 18. Treatment with VGX-3100, Inovio's HPV16/18-specific immunotherapy, resulted in histopathological regression of CIN2/3 to CIN1 or no disease, meeting the study's primary endpoint. In addition, the trial demonstrated clearance of HPV in conjunction with regression of cervical lesions. Robust T-cell activity was detected in subjects who received VGX-3100 compared to those who received placebo.
Inovio Biomedical Has Returned 22.4% Since SmarTrend Recommendation (INO)
Comtex SmarTrend(R) - Tue Jul 22, 9:24AM CDT
SmarTrend identified an Uptrend for Inovio Biomedical (AMEX:INO) on June 6th, 2014 at $9.41. In approximately 2 months, Inovio Biomedical has returned 22.44% as of today's recent price of $11.52.
Roundtable: 3 Stocks Janet Yellen Would Hate
Motley Fool Staff - Motley Fool - Sun Jul 20, 8:15AM CDT
In the Fed's Monetary Policy Report submitted July 15th, Fed chair Janet Yellen called out social media and biotech stocks as having valuations that appear "substantially stretched" (i.e. overvalued). We asked our top contributors for stocks where...
Biotech Stock Mailbag: MannKind, Bluebird, Northwest Bio, More '14 Tradable Biotech Events
at The Street - Mon Jul 14, 8:30AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
Biotech Stocks Highlight -- Research on Celgene, Inovio Pharma, Amgen, and Array BioPharma
PR Newswire - Wed Jul 09, 5:40AM CDT
On Tuesday, July 08, 2014, the NASDAQ Composite ended at 4,391.46, down 1.35%, the Dow Jones Industrial Average finished the day 0.69% lower at 16,906.62, and the S&P 500 closed at 1,963.71, down 0.70%. The losses were broad based as nine out of ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 709.36, down 0.92%, while the index has advanced 2.11% in the last one month. Investor-Edge has initiated coverage on the following equities: Celgene Corp. (NASDAQ: CELG), Inovio Pharmaceuticals Inc. (NYSE MKT: INO), Amgen Inc. (NASDAQ: AMGN) and Array BioPharma Inc. (NASDAQ: ARRY). Free technical research on CELG, INO, AMGN and ARRY can be downloaded upon signing up at:
Uptrend Call Working As Inovio Biomedical Stock Rises 8.5% (INO)
Comtex SmarTrend(R) - Tue Jul 08, 11:17AM CDT
SmarTrend identified an Uptrend for Inovio Biomedical (AMEX:INO) on June 6th, 2014 at $9.41. In approximately 1 month, Inovio Biomedical has returned 8.50% as of today's recent price of $10.21.
Why Merck Should Buy Inovio, Seattle Genetics, or MannKind
Leo Sun, The Motley Fool - Motley Fool - Tue Jul 01, 7:37AM CDT
Merck is currently considering major acquisitions of biotech companies to diversify its drug portfolio, according to research chief Roger Perlmutter's statement at the annual Goldman Sachs health care conference earlier this month. This...
Inovio Pharmaceuticals Added To Russell Global, Russell 2000® and Russell Microcap® Indexes
PR Newswire - Tue Jul 01, 3:00AM CDT
Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced that it has been added to the Russell Global, Russell 2000 and Russell Microcap Indexes. Each June, Russell realigns its family of global equity indexes to reflect market changes in the past year. Approximately $5.2 trillion in assets are currently benchmarked to Russell Indexes.
Uptrend Call Working As Inovio Biomedical Stock Rises 20.6% (INO)
Comtex SmarTrend(R) - Mon Jun 30, 9:28AM CDT
SmarTrend identified an Uptrend for Inovio Biomedical (AMEX:INO) on June 6th, 2014 at $9.41. In approximately 3 weeks, Inovio Biomedical has returned 20.62% as of today's recent price of $11.35.
5 of Last Week's Biggest Winners
Rick Munarriz, The Motley Fool - Motley Fool - Sun Jun 29, 12:00PM CDT
It was a mixed week on Wall Street, with the Nasdaq moving higher and the Dow moving lower, but there were plenty of stocks really making some serious moves. Let's take a closer look at five of this past week's biggest scorchers. Company ...
Inovio Pharmaceuticals to Host Second Quarter 2014 Financial Results Call on August 11, 2014
PR Newswire - Fri Aug 01, 7:00AM CDT
Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that it will host a conference call to report its second quarter 2014 financial results on Monday, August 11, 2014 at 9:00 AM ET. CEO Dr. J. Joseph Kim and CFO Peter Kies will discuss second quarter earnings, provide a corporate update, and participate in a live Q&A with analysts. The update will include clinical development plans for VGX-3100, Inovio's immune therapy targeting pre-cancers and cancers associated with HPV.
23.2% Return Seen to Date on SmarTrend Inovio Biomedical Call (INO)
Comtex SmarTrend(R) - Tue Jul 29, 9:46AM CDT
SmarTrend identified an Uptrend for Inovio Biomedical (AMEX:INO) on June 6th, 2014 at $9.41. In approximately 2 months, Inovio Biomedical has returned 23.16% as of today's recent price of $11.59.
What Do Short-Sellers Have Against These 3 Companies?
Sean Williams, The Motley Fool - Motley Fool - Mon Jul 28, 10:25AM CDT
The best thing about the stock market is that you can make money in either direction . Historically, stock indexes tend to trend upward over the long term. But when you look at individual stocks, you'll find plenty that lose money over the long...
This Week in Biotech: Puma Sprints, Gilead Sweeps, and Inovio Hits the Mark
Sean Williams, The Motley Fool - Motley Fool - Sat Jul 26, 12:32PM CDT
With the SPDR S&P Biotech Index up 22% over the trailing 12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and...
Upgrade Alert for Inovio Biomedical (INO)
Comtex SmarTrend(R) - Fri Jul 25, 6:55AM CDT
Inovio Biomedical (AMEX:INO) was upgraded from Hold to Buy at Aegis today. The stock closed yesterday at $12.94 on volume of 3.6 million shares, above average daily volume of 1.7 million. Over the past year, Inovio Biomedical has traded in a range of $1.22 to $14.20 and closed yesterday at $12.98, 964% above that low. The 200-day and 50-day moving averages have moved 3.99% higher and 8.45% higher over the past week, respectively.
3 Game-Changing Stories That Shook Investors: Inovio Pharmaceuticals, Gilead Sciences, and GlaxoSmit
George Budwell, The Motley Fool - Motley Fool - Thu Jul 24, 1:05PM CDT
The health care sector exploded with major news events yesterday, fueled by second-quarter earnings, clinical trial updates, and even unexpected regulatory events. Given that the day's headlines seemed to be dominated by Puma Biotechnology 's...
The S&P 500 Closes at Yet Another All-Time Closing High on No Volume
at The Street - Wed Jul 23, 4:34PM CDT
The stock indexes closed mixed on Wednesday with the S&P 500 setting a new all-time closing high.
After Yesterday's Rally of 17.59% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Wed Jul 23, 4:25PM CDT
Inovio Biomedical (AMEX:INO) traded in a range yesterday that spanned from a low of $12.00 to a high of $14.20. Yesterday, the shares gained 17.6%, which took the trading range above the 3-day high of $11.60 on volume of 12.9 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Why Inovio Pharmaceuticals Inc Stock Livened Up Today
Dan Carroll, The Motley Fool - Motley Fool - Wed Jul 23, 1:21PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Inovio Pharmaceuticals , a clinical-stage...
Inovio Declares Spin-Laden Victory With DNA Vaccine
at The Street - Wed Jul 23, 9:17AM CDT
Inovio's analysis of the VGX-3100 study omits an unknown number of patients, calling the results into question.
Inovio Pharmaceuticals HPV Immunotherapy Achieves Primary Efficacy Endpoint in Randomized Phase II Cervical Dysplasia Trial
PR Newswire - Wed Jul 23, 8:15AM CDT
Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) today announced successful results from its randomized, double-blind, placebo-controlled phase II trial of VGX-3100 in women with biopsy-proven cervical intraepithelial neoplasia 2/3 (CIN2/3) associated with human papillomavirus (HPV) types 16 or 18. Treatment with VGX-3100, Inovio's HPV16/18-specific immunotherapy, resulted in histopathological regression of CIN2/3 to CIN1 or no disease, meeting the study's primary endpoint. In addition, the trial demonstrated clearance of HPV in conjunction with regression of cervical lesions. Robust T-cell activity was detected in subjects who received VGX-3100 compared to those who received placebo.
Inovio Biomedical Has Returned 22.4% Since SmarTrend Recommendation (INO)
Comtex SmarTrend(R) - Tue Jul 22, 9:24AM CDT
SmarTrend identified an Uptrend for Inovio Biomedical (AMEX:INO) on June 6th, 2014 at $9.41. In approximately 2 months, Inovio Biomedical has returned 22.44% as of today's recent price of $11.52.
Roundtable: 3 Stocks Janet Yellen Would Hate
Motley Fool Staff - Motley Fool - Sun Jul 20, 8:15AM CDT
In the Fed's Monetary Policy Report submitted July 15th, Fed chair Janet Yellen called out social media and biotech stocks as having valuations that appear "substantially stretched" (i.e. overvalued). We asked our top contributors for stocks where...
Biotech Stock Mailbag: MannKind, Bluebird, Northwest Bio, More '14 Tradable Biotech Events
at The Street - Mon Jul 14, 8:30AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
Biotech Stocks Highlight -- Research on Celgene, Inovio Pharma, Amgen, and Array BioPharma
PR Newswire - Wed Jul 09, 5:40AM CDT
On Tuesday, July 08, 2014, the NASDAQ Composite ended at 4,391.46, down 1.35%, the Dow Jones Industrial Average finished the day 0.69% lower at 16,906.62, and the S&P 500 closed at 1,963.71, down 0.70%. The losses were broad based as nine out of ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 709.36, down 0.92%, while the index has advanced 2.11% in the last one month. Investor-Edge has initiated coverage on the following equities: Celgene Corp. (NASDAQ: CELG), Inovio Pharmaceuticals Inc. (NYSE MKT: INO), Amgen Inc. (NASDAQ: AMGN) and Array BioPharma Inc. (NASDAQ: ARRY). Free technical research on CELG, INO, AMGN and ARRY can be downloaded upon signing up at:
Uptrend Call Working As Inovio Biomedical Stock Rises 8.5% (INO)
Comtex SmarTrend(R) - Tue Jul 08, 11:17AM CDT
SmarTrend identified an Uptrend for Inovio Biomedical (AMEX:INO) on June 6th, 2014 at $9.41. In approximately 1 month, Inovio Biomedical has returned 8.50% as of today's recent price of $10.21.
Why Merck Should Buy Inovio, Seattle Genetics, or MannKind
Leo Sun, The Motley Fool - Motley Fool - Tue Jul 01, 7:37AM CDT
Merck is currently considering major acquisitions of biotech companies to diversify its drug portfolio, according to research chief Roger Perlmutter's statement at the annual Goldman Sachs health care conference earlier this month. This...
Inovio Pharmaceuticals Added To Russell Global, Russell 2000® and Russell Microcap® Indexes
PR Newswire - Tue Jul 01, 3:00AM CDT
Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced that it has been added to the Russell Global, Russell 2000 and Russell Microcap Indexes. Each June, Russell realigns its family of global equity indexes to reflect market changes in the past year. Approximately $5.2 trillion in assets are currently benchmarked to Russell Indexes.
Uptrend Call Working As Inovio Biomedical Stock Rises 20.6% (INO)
Comtex SmarTrend(R) - Mon Jun 30, 9:28AM CDT
SmarTrend identified an Uptrend for Inovio Biomedical (AMEX:INO) on June 6th, 2014 at $9.41. In approximately 3 weeks, Inovio Biomedical has returned 20.62% as of today's recent price of $11.35.
5 of Last Week's Biggest Winners
Rick Munarriz, The Motley Fool - Motley Fool - Sun Jun 29, 12:00PM CDT
It was a mixed week on Wall Street, with the Nasdaq moving higher and the Dow moving lower, but there were plenty of stocks really making some serious moves. Let's take a closer look at five of this past week's biggest scorchers. Company ...
